![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Saturday, October 10, 2015 3:39:01 AM
http://pranabio.com/wp-content/uploads/2015/08/150826_Prana-Annual-Report-and-4E.pdf
That would be brilliant if the patients were more advanced, but the differences over one year in these earlier stage patients would possibly have been tiny. I would take from that data that PBT2 may have stopped or slowed AD in the second year but the trial is too small to be able to reach that conclusion. Still, no changes over one year is a good sign.
When Prana started the Reach2HD and IMAGINE trials it was always the plan that Reach2HD would lead PBT2 to market and IMAGINE was run to try to attract a pharma partner for the AD program with a demonstration of target engagement.
They are still on track with HD for phase3, and like you I don't think they will have a problem getting the partial hold lifted when the safety analysis and HD trial design are complete.
PickleJar Unveils Latest Venue Managed Services Innovations in Upcoming Webinar • PKLE • Aug 23, 2024 1:11 PM
Element79 Gold Corp Provides Update on Nevada Portfolio • ELMGF • Aug 23, 2024 8:00 AM
Maybacks Adds Award Winning Show to Its Lineup Discusses Maybacks Opportunity • AHRO • Aug 22, 2024 11:30 AM
North Bay Resources Announces First Gold Concentrate at Mt. Vernon Gold Mine, Assays 12 oz/ton Gold, 17.5 oz/ton Platinum, and 8 oz./ton Silver, Sierra County, California • NBRI • Aug 22, 2024 10:28 AM
All Things Mobile Analytic, Inc. Reports Major Growth with Over $11 Million in Revenue • ATMH • Aug 22, 2024 7:19 AM
Unitronix Announces Strategic Entry into Cryptocurrency Space • UTRX • Aug 21, 2024 10:00 AM